News & Updates

Patients with bladder cancer suffer from high rates of sexual dysfunction, especially those who have undergone radical treatments, a recent study has found.

In clinical trials of patients with unresectable metastatic colorectal cancer (mCRC), conversion to resectability (C2R) rarely happens, reveals a study.

The combination of abiraterone and olaparib conferred significant improvement in radiographic progression-free survival (rPFS) in the first-line treatment of metastatic castration-resistant prostate cancer (mCRPC), according to findings from the phase III PROpel trial presented at EAU 2022.

MammaPrint, a signature test that includes 70 genes, appears to accurately identify hormone receptor-positive breast cancer (HR+BC) patients who are at ultra-low risk of distant recurrence, reports a recent study.

Adhering to a healthy lifestyle may be a means to counteract the genetic risk of lethal prostate cancer, a study finds.